What are the indications, dosing schedule, contraindications, and common side effects of Nurtec (rimegepant) for acute and preventive migraine treatment?

Nurtec (Rimegepant) for Migraine Treatment

Nurtec ODT (rimegepant) is FDA-approved for both acute treatment of migraine attacks and preventive treatment of episodic migraine in adults, with a dose of 75 mg for both indications but different dosing schedules. 1

Indications

Rimegepant has two distinct FDA-approved indications:

• Acute treatment: Migraine with or without aura in adults 1
• Preventive treatment: Episodic migraine in adults 1

According to the 2025 American College of Physicians guidelines, rimegepant is positioned as a third-line option for acute treatment—to be considered only after inadequate response or intolerance to combination therapy of a triptan plus NSAID or acetaminophen 2. For prevention, rimegepant is among several options that can be initiated as monotherapy for episodic migraine (1-14 headache days per month) 3.

Dosing Schedule

Acute Treatment

• Dose: 75 mg taken orally as needed when migraine occurs 1
• Maximum: One tablet per 24-hour period 1
• Safety limit: No more than 18 doses in a 30-day period (safety beyond this not established) 1

Preventive Treatment

• Dose: 75 mg taken orally every other day 1
• Long-term data: Demonstrated sustained efficacy and safety over 52 weeks 4

Administration

• Place the orally disintegrating tablet on or under the tongue using dry hands 1
• Dissolves without water 1
• Take immediately after opening blister pack 1

Contraindications

The only absolute contraindication is a history of hypersensitivity reaction to rimegepant or any component of Nurtec ODT, including anaphylaxis and delayed serious hypersensitivity reactions 1.

Important Drug Interactions Requiring Dose Adjustments

• Strong CYP3A4 inhibitors: Avoid concomitant use 1
• Moderate CYP3A4 inhibitors: Avoid another dose within 48 hours 1
• Strong or moderate CYP3A inducers: Avoid concomitant use (may lead to loss of efficacy) 1
• Potent P-gp inhibitors: Avoid another dose within 48 hours 1

Special Populations

• Pregnancy: Unknown safety; pregnancy registry available (MONITOR registry: 1-877-366-0324) 1
• Breastfeeding: Small amounts pass into breast milk; discuss with provider 1
• Liver/kidney problems: Inform provider before use 1

Common Side Effects

Acute Treatment

The most common side effect is:

• Nausea 1

Preventive Treatment

The most common side effects are:

• Nausea
• Stomach pain
• Indigestion 1

Clinical trial data showed adverse events were generally mild, with similar rates to placebo in acute treatment studies (nausea 0.9% vs 1.1%, dizziness 0.7% vs 0.4%) 5. In the 52-week preventive treatment study, only 2.3% reported severe adverse events and 2.8% discontinued due to adverse events 4.

Serious Warnings

Hypersensitivity Reactions

• Can occur days after administration 1
• Symptoms include swelling of face/mouth/tongue/throat, trouble breathing, rash 1
• Discontinue immediately and seek emergency care if these occur 1

Cardiovascular Concerns

• Hypertension: May cause or worsen high blood pressure 1
• Raynaud's phenomenon: May worsen circulation problems in fingers/toes (numbness, color changes from pale to blue to red) 1

Hepatotoxicity

No signal of drug-induced liver injury was identified in clinical trials, including the 52-week extension study where no participant had ALT/AST >3× ULN concurrent with total bilirubin >2× ULN 4, 5, 6.

Clinical Positioning

When to Use Rimegepant

For acute treatment, the ACP guidelines recommend a stepwise approach:

1. Start with NSAID or acetaminophen at adequate doses
2. If inadequate relief, add a triptan to NSAID (or acetaminophen if NSAIDs contraindicated)
3. Only consider rimegepant if triptan + NSAID/acetaminophen combination fails or is not tolerated 2

A 2025 phase 4 trial specifically demonstrated rimegepant's efficacy in triptan-unsuitable patients (those with intolerance, lack of efficacy, or contraindications to ≥2 triptans), showing 55.9% achieved pain relief at 2 hours versus 32.7% with placebo 7.

For preventive treatment, rimegepant can be initiated as first-line monotherapy for episodic migraine alongside other options like beta-blockers, antiseizure medications, or CGRP monoclonal antibodies 3.

Key Clinical Pearls

• Dual indication advantage: Rimegepant is the first agent approved for both acute and preventive treatment, allowing simplified regimens 8
• Medication overuse headache: Unlike triptans (≥10 days/month threshold), gepants have not been definitively associated with medication overuse headache, though the 18-dose monthly limit suggests caution 2
• Cardiovascular safety: Unlike triptans, rimegepant does not cause vasoconstriction, making it suitable for patients with cardiovascular contraindications to triptans 7
• Onset of action: The orally disintegrating formulation may provide faster response than conventional tablets 8